Pharmacogenomics of beta-blockers and statins: Possible implications for perioperative cardiac complications

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 26, Issue 6, 2012, Pages 1101-1114

  Kertai, Miklos D ^a   Fontes, Manuel ^a   Podgoreanu, Mihai V ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

blockers; perioperative cardiac complication; pharmacogenomics; statins

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; ATENOLOL; ATORVASTATIN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; G PROTEIN BETA3 SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KINESIN; KINESIN LIKE PROTEIN 6; LABETALOL; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN 1; PLACEBO; PRAVASTATIN; PROPRANOLOL; ROSUVASTATIN; SIMVASTATIN; TIMOLOL; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; AMINO ACID SUBSTITUTION; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CARDIAC PATIENT; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART SURGERY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERTENSION; HYPOTENSION; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MYOPATHY; NONHUMAN; PEROPERATIVE COMPLICATION; PHARMACOGENOMICS; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; HEART DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PERIOPERATIVE CARE; PHARMACOGENETICS;

EID: 84868303069     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2012.06.025     Document Type: Review

References (122)

1. L.A. Fleisher, J.A. Beckman, K.A. Brown ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines on perioperative cardiovascular evaluation for noncardiac surgery): Developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery Circulation 116 2007 e418 e499
2. L.A. Fleisher, J.A. Beckman, K.A. Brown ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery J Am Coll Cardiol 54 2009 e13 e118
3. P.K. Lindenauer, P. Pekow, K. Wang Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery JAMA 291 2004 2092 2099
4. P.K. Lindenauer, P. Pekow, K. Wang Perioperative beta-blocker therapy and mortality after major noncardiac surgery N Engl J Med 353 2005 349 361
5. N. Eldrup, J. Budtz-Lilly, J. Laustsen Long-term incidence of myocardial infarct, stroke, and mortality in patients operated on for abdominal aortic aneurysms J Vasc Surg 55 2012 311 317
6. M.D. Kertai, E. Boersma, C.M. Westerhout Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery Am J Med 116 2004 96 103
7. A.W. Wallace, S. Au, B.A. Cason Association of the pattern of use of perioperative beta-blockade and postoperative mortality Anesthesiology 113 2010 794 805
8. Y. Le Manach, C. Ibanez Esteves, M. Bertrand Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing vascular surgery Anesthesiology 114 2011 98 104
9. M.D. Kertai, E. Boersma, C.M. Westerhout A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery Eur J Vasc Endovasc Surg 28 2004 343 352
10. R.G. Badgett, V.A. Lawrence, S.L. Cohn Variations in pharmacology of beta-blockers may contribute to heterogeneous results in trials of perioperative beta-blockade Anesthesiology 113 2010 585 592
11. A. Ghatak, O. Faheem, P.D. Thompson The genetics of statin-induced myopathy Atherosclerosis 210 2010 337 343
12. J.A. Johnson, L.H. Cavallari, A.L. Beitelshees Pharmacogenomics: Application to the management of cardiovascular disease Clin Pharmacol Ther 90 2011 519 531
13. R. Myburgh, W.E. Hochfeld, T.M. Dodgen Cardiovascular pharmacogenetics Pharmacol Ther 133 2012 280 290
14. S.B. Liggett Polymorphisms of adrenergic receptors: Variations on a theme Assay Drug Dev Technol 1 2003 317 326
15. D.T. Mangano Perioperative cardiac morbidity Anesthesiology 72 1990 153 184
16. P.J. Devereaux, H. Yang, S. Yusuf Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): A randomised controlled trial Lancet 371 2008 1839 1847
17. J.A. Johnson, I. Zineh, B.J. Puckett Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol Clin Pharmacol Ther 74 2003 44 52
18. J.A. Johnson, S.B. Liggett Cardiovascular pharmacogenomics of adrenergic receptor signaling: Clinical implications and future directions Clin Pharmacol Ther 89 2011 366 378
19. S.B. Liggett Genetic, molecular, and clinical characterization of adrenergic receptor polymorhisms D.M. Perez, The adrenergic Receptors 2005 Humana Press Totowa, NJ 339 364
20. H. Cythchrome P450 (CYP) allele nomenclature committee http://www.cypalleles.ki.se/cyp2d6.htm Accessed February 23, 2012
21. S.F. Zhou Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I Clin Pharmacokinet 48 2009 689 723
22. M. Ingelman-Sundberg, S.C. Sim, A. Gomez Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol Ther 116 2007 496 526
23. E. Aklillu, I. Persson, L. Bertilsson Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles J Pharmacol Exp Ther 278 1996 441 446
24. J. Shin, J.A. Johnson Pharmacogenetics of beta-blockers Pharmacotherapy 27 2007 874 887
25. M.S. Lennard, J.H. Silas, S. Freestone Oxidation phenotype - A major determinant of metoprolol metabolism and response N Engl J Med 307 1982 1558 1560
26. X. Deroubaix, R.L. Lins, S. Lens Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers Int J Clin Pharmacol Ther 34 1996 61 70
27. M.J. Bijl, L.E. Visser, R.H. van Schaik Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users Clin Pharmacol Ther 85 2009 45 50
28. T. Rau, H. Wuttke, L.M. Michels Impact of the CYP2D6 genotype on the clinical effects of metoprolol: A prospective longitudinal study Clin Pharmacol Ther 85 2009 269 272
29. H. Wuttke, T. Rau, R. Heide Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects Clin Pharmacol Ther 72 2002 429 437
30. K. Goryachkina, A. Burbello, S. Boldueva CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction Eur J Clin Pharmacol 64 2008 1163 1173
31. R. Fux, K. Mörike, A.M. Pröhmer Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study Clin Pharmacol Ther 78 2005 378 387
32. T. Frielle, S. Collins, K.W. Daniel Cloning of the cDNA for the human beta 1-adrenergic receptor Proc Natl Acad Sci U S A 84 1987 7920 7924
33. D.A. Mason, J.D. Moore, S.A. Green A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor J Biol Chem 274 1999 12670 12674
34. S. Podlowski, K. Wenzel, H.P. Luther Beta1-adrenoceptor gene variations: A role in idiopathic dilated cardiomyopathy? J Mol Med 78 2000 87 93
35. D.A. Rathz, K.M. Brown, L.A. Kramer Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking J Cardiovasc Pharmacol 39 2002 155 160
36. A. Sandilands, G. Yeo, M.J. Brown Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms Pharmacogenetics 14 2004 343 349
37. S.B. Liggett Beta2-adrenergic receptor polymorphisms and sudden cardiac death: A signal to follow Circulation 113 2006 1818 1820
38. M.C. Levin, S. Marullo, O. Muntaner The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation J Biol Chem 277 2002 30429 30435
39. M.A. Pacanowski, Y. Gong, R.M. Cooper-Dehoff Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension Clin Pharmacol Ther 84 2008 715 721
40. H. Bruck, K. Leineweber, T. Temme The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity J Am Coll Cardiol 46 2005 2111 2115
41. J. Liu, Z.Q. Liu, Z.R. Tan Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol Clin Pharmacol Ther 74 2003 372 379
42. G.G. Sofowora, V. Dishy, M. Muszkat A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade Clin Pharmacol Ther 73 2003 366 371
43. M. Zaugg, L. Bestmann, J. Wacker Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: The Swiss Beta blocker in spinal Anesthesia (BBSA) study: A double-blinded, placebo-controlled, multicenter trial with 1-year follow-up Anesthesiology 107 2007 33 44
44. B. Parvez, N. Chopra, S. Rowan A common beta1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation J Am Coll Cardiol 59 2012 49 56
45. B.K. Kobilka, R.A. Dixon, T. Frielle cDNA for the human beta 2-adrenergic receptor: A protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor Proc Natl Acad Sci U S A 84 1987 46 50
46. S.A. Green, J. Turki, M. Innis Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties Biochemistry 33 1994 9414 9419
47. S.A. Green, G. Cole, M. Jacinto A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor J Biol Chem 268 1993 23116 23121
48. Z.H. Tseng, B.E. Aouizerat, L. Pawlikowska Common beta-adrenergic receptor polymorphisms are not associated with risk of sudden cardiac death in patients with coronary artery disease Heart Rhythm 5 2008 814 821
49. R.N. Lemaitre, S.R. Heckbert, N. Sotoodehnia Beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke Am J Hypertens 21 2008 290 296
50. C. Forleo, N. Resta, S. Sorrentino Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy Am J Med 117 2004 451 458
51. S.M. Wallerstedt, A.L. Eriksson, C. Ohlsson Haplotype association analysis of the polymorphisms Arg16Gly and Gln27Glu of the adrenergic beta2 receptor in a Swedish hypertensive population J Hum Hypertens 19 2005 705 708
52. D.E. Lanfear, P.G. Jones, S. Marsh Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome JAMA 294 2005 1526 1533
53. V. Dishy, R. Landau, G.G. Sofowora Beta2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo Pharmacogenetics 14 2004 517 522
54. M. Thomsen, M. Dahl, A. Tybjaerg-Hansen Beta(2) -adrenergic receptor Thr164IIe polymorphism, blood pressure and ischaemic heart disease in 66 750 individuals J Intern Med 271 2012 305 314
55. S.B. Liggett, L.E. Wagoner, L.L. Craft The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure J Clin Invest 102 1998 1534 1539
56. M.D. Littlejohn, B.R. Palmer, A.M. Richards Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatment Eur J Heart Fail 10 2008 55 59
57. F. Piscione, G. Iaccarino, G. Galasso Effects of Ile164 polymorphism of beta2-adrenergic receptor gene on coronary artery disease J Am Coll Cardiol 52 2008 1381 1388
58. L.J. Emorine, S. Marullo, M.M. Briend-Sutren Molecular characterization of the human beta 3-adrenergic receptor Science 245 1989 1118 1121
59. C. Gauthier, B. Rozec, B. Manoury Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies Curr Heart Fail Rep 8 2011 184 192
60. W. Vrydag, A.E. Alewijnse, M.C. Michel Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors? Br J Pharmacol 156 2009 127 134
61. J. Walston, K. Silver, C. Bogardus Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene N Engl J Med 333 1995 343 347
62. M.R. Candelore, L. Deng, L.M. Tota Pharmacological characterization of a recently described human beta 3-adrenergic receptor mutant Endocrinology 137 1996 2638 2641
63. F. Piétri-Rouxel, B. St John Manning, J. Gros The biochemical effect of the naturally occurring Trp64 - >Arg mutation on human beta3-adrenoceptor activity Eur J Biochem 247 1997 1174 1179
64. M.H. Zafarmand, Y.T. van der Schouw, D.E. Grobbee T64A polymorphism in beta3-adrenergic receptor gene (ADRB3) and coronary heart disease: A case-cohort study and meta-analysis J Intern Med 263 2008 79 89
65. D.J. van Veldhuisen, A. Cohen-Solal, M. Böhm Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data from SENIORS (study of effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart failure) J Am Coll Cardiol 53 2009 2150 2158
66. B. Rozec, M. Erfanian, K. Laurent Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart J Am Coll Cardiol 53 2009 1532 1538
67. J. Inglese, N.J. Freedman, W.J. Koch Structure and mechanism of the G protein-coupled receptor kinases J Biol Chem 268 1993 23735 23738
68. S.B. Liggett, S. Cresci, R.J. Kelly A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure Nat Med 14 2008 510 517
69. S. Cresci, R.J. Kelly, T.P. Cappola Clinical and genetic modifiers of long-term survival in heart failure J Am Coll Cardiol 54 2009 432 444
70. M. Iwase, M. Uechi, D.E. Vatner Cardiomyopathy induced by cardiac Gs alpha overexpression Am J Physiol 272 1997 H585 H589
71. U.H. Frey, E. Kottenberg, M. Kamler Genetic interactions in the beta-adrenoceptor/G-protein signal transduction pathway and survival after coronary artery bypass grafting: A pilot study Br J Anaesth 107 2011 869 878
72. U.H. Frey, M. Adamzik, E. Kottenberg-Assenmacher A novel functional haplotype in the human GNAS gene alters Galphas expression, responsiveness to beta-adrenoceptor stimulation, and peri-operative cardiac performance Eur Heart J 30 2009 1402 1410
73. M.C. Gerson, L.E. Wagoner, N. McGuire Activity of the uptake-1 norepinephrine transporter as measured by I-123 MIBG in heart failure patients with a loss-of-function polymorphism of the presynaptic alpha2C-adrenergic receptor J Nucl Cardiol 10 2003 583 589
74. K.M. Small, L.E. Wagoner, A.M. Levin Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure N Engl J Med 347 2002 1135 1142
75. M. Brede, F. Wiesmann, R. Jahns Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure Circulation 106 2002 2491 2496
76. M.R. Bristow, G.A. Murphy, H. Krause-Steinrauf An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker Bucindolol in chronic heart failure Circ Heart Fail 3 2010 21 28
77. M.T. Lobmeyer, Y. Gong, S.G. Terra Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure Pharmacogenet Genomics 17 2007 277 282
78. S.C. Smith Jr, J. Allen, S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute J Am Coll Cardiol 47 2006 2130 2139
79. M.D. Kertai, J. Klein, J.J. Bax Predicting perioperative cardiac risk Prog Cardiovasc Dis 47 2005 240 257
80. P.L. van Haelst, J.J. van Doormaal, J.F. May Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein Eur J Intern Med 12 2001 503 509
81. R.S. Rosenson, C.C. Tangney Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction JAMA 279 1998 1643 1650
82. B.J. Peters, O.H. Klungel, A. de Boer Genetic determinants of response to statins Expert Rev Cardiovasc Ther 7 2009 977 983
83. L.M. Mangravite, C.F. Thorn, R.M. Krauss Clinical implications of pharmacogenomics of statin treatment Pharmacogenomics J 6 2006 360 374
84. M.L. Becker, L.E. Visser, R.H. van Schaik Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males Pharmacogenomics 10 2009 1743 1751
85. National Center for Biotechnology Single nucleotide polymorphisms http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Retrieve&dopt= full-report&list-uids=5243 Accessed: March 9, 2012
86. I. Cascorbi Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs Pharmacol Ther 112 2006 457 473
87. R.B. Kim, B.F. Leake, E.F. Choo Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 2001 189 199
88. C. Kimchi-Sarfaty, J.M. Oh, I.W. Kim A "silent" polymorphism in the MDR1 gene changes substrate specificity Science 315 2007 525 528
89. C. Chen, R.J. Mireles, S.D. Campbell Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1 Drug Metab Dispos 33 2005 537 546
90. J.E. Keskitalo, K.J. Kurkinen, P.J. Neuvoneni ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin Clin Pharmacol Ther 84 2008 457 461
91. M. Fiegenbaum, F.R. da Silveira, C.R. Van der Sand The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment Clin Pharmacol Ther 78 2005 551 558
92. K. Kajinami, M.E. Brousseau, J.M. Ordovas Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner Am J Cardiol 93 2004 1046 1050
93. B.J. Peters, A.S. Rodin, O.H. Klungel Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction Pharmacogenomics 11 2010 1065 1076
94. A. Kashani, C.O. Phillips, J.M. Foody Risks associated with statin therapy: A systematic overview of randomized clinical trials Circulation 114 2006 2788 2797
95. M.A. Silva, A.C. Swanson, P.J. Gandhi Statin-related adverse events: A meta-analysis Clin Ther 28 2006 26 35
96. S. Bellosta, R. Paoletti, A. Corsini Safety of statins: Focus on clinical pharmacokinetics and drug interactions Circulation 109 2004 III50 III57
97. L.R. Brunham, P.J. Lansberg, L. Zhang Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin Pharmacogenomics J 12 2011 233 237
98. R.G. Tirona, B.F. Leake, G. Merino Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans J Biol Chem 276 2001 35669 35675
99. M.K. Pasanen, M. Neuvonen, P.J. Neuvonen SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid Pharmacogenet Genomics 16 2006 873 879
100. M.K. Pasanen, H. Fredrikson, P.J. Neuvonen Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin Clin Pharmacol Ther 82 2007 726 733
101. O.A. Iakoubova, C.H. Tong, C.M. Rowland Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: The CARE and WOSCOPS trials J Am Coll Cardiol 51 2008 435 443
102. O.A. Iakoubova, M.S. Sabatine, C.M. Rowland Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: Results from the PROVE IT-TIMI 22 study J Am Coll Cardiol 51 2008 449 455
103. H. Miki, Y. Okada, N. Hirokawa Analysis of the kinesin superfamily: Insights into structure and function Trends Cell Biol 15 2005 467 476
104. A. Lupas, M. Van Dyke, J. Stock Predicting coiled coils from protein sequences Science 252 1991 1162 1164
105. B.J. Arsenault, S.M. Boekholdt, G.K. Hovingh The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in End Points through aggressive lipid-lowering prospective studies Circ Cardiovasc Genet 5 2012 51 57
106. P.M. Ridker, J.G. MacFadyen, R.J. Glynn Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention Circ Cardiovasc Genet 4 2011 312 317
107. S. Akira, K. Takeda, T. Kaisho Toll-like receptors: Critical proteins linking innate and acquired immunity Nat Immunol 2 2001 675 680
108. N.C. Arbour, E. Lorenz, B.C. Schutte TLR4 mutations are associated with endotoxin hyporesponsiveness in humans Nat Genet 25 2000 187 191
109. S. Kiechl, E. Lorenz, M. Reindl Toll-like receptor 4 polymorphisms and atherogenesis N Engl J Med 347 2002 185 192
110. S.M. Boekholdt, W.R. Agema, R.J. Peters Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events Circulation 107 2003 2416 2421
111. W. Siffert, D. Rosskopf, G. Siffert Association of a human G-protein beta3 subunit variant with hypertension Nat Genet 18 1998 45 48
112. W. Siffert, P. Forster, K.H. Jöckel Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals J Am Soc Nephrol 10 1999 1921 1930
113. N. von Beckerath, Y. Schusterschitz, W. Koch G protein beta 3 subunit 825T allele carriage and risk of coronary artery disease Atherosclerosis 167 2003 135 139
114. C.K. Naber, J. Hüsing, U. Wolfhard Interaction of the ACE D allele and the GNB3 825T allele in myocardial infarction Hypertension 36 2000 986 989
115. A.C. Nicholson, D.P. Hajjar Transforming growth factor-beta up-regulates low density lipoprotein receptor-mediated cholesterol metabolism in vascular smooth muscle cells J Biol Chem 267 1992 25982 25987
116. Y. Yamada, H. Izawa, S. Ichihara Prediction of the risk of myocardial infarction from polymorphisms in candidate genes N Engl J Med 347 2002 1916 1923
117. C. Hengstenberg, H. Schunkert, B. Mayer Association between a polymorphism in the G protein beta3 subunit gene (GNB3) with arterial hypertension but not with myocardial infarction Cardiovasc Res 49 2001 820 827
118. W. Renner, M.M. Hoffmann, G. Grünbacher G-protein beta3 subunit (GNB3) gene polymorphisms and cardiovascular disease: The Ludwigshafen risk and cardiovascular health (LURIC) study Atherosclerosis 192 2007 108 112
119. B.J. Peters, A.H. Maitland-van der Zee, B.H. Stricker Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant Pharmacogenet Genomics 18 2008 631 636
120. H. Yuan, Z. Huang, G. Yang Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol J Int Med Res 36 2008 1354 1362
121. E.M. McDonagh, M. Whirl-Carrillo, Y. Garten From pharmacogenomic knowledge acquisition to clinical applications: The PharmGKB as a clinical pharmacogenomic biomarker resource Biomark Med 5 2011 795 806
122. P. Nagele, S.B. Liggett Genetic variation, β-blockers, and perioperative myocardial infraction Anesthesiology 115 2011 1316 1327